Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.47 |
| ▸ | PPARG | P37231 | 8/20 | 0.47 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2323692 | 1.00 | PPARA (0.47) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL6337223 | 1.00 | PPARA (0.47) | PPARAPPARGCTSKCTSSACE | |
| Benzene SCHEMBL28847299 | 0.97 | PPARA (0.51) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL617475 | 0.92 | PPARA (0.48) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL2564729 | 0.92 | PPARA (0.48) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL617476 | 0.92 | PPARA (0.48) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL2726974 | 0.91 | CTSK (0.51) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL211798 | 0.91 | CTSK (0.51) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL211797 | 0.91 | CTSK (0.51) | PPARAPPARGCTSKCTSSACE | |
| SCHEMBL22283971 | 0.90 | CTSK (0.46) | PPARAPPARGCTSKCTSSACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473291-B2 | Benzodiazepine compound, preparation method therefor, and use thereof in medicine | WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) | 2025-11-18 | — | — | US | claimed |
| CN-115068624-B | Peptide dendrimer drug-carrying system and preparation method and application thereof | 重庆理工大学 | 2024-02-13 | — | — | CN | claimed |
| US-20220324867-A1 | BENZODIAZEPINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | WEST CHINA HOSPITAL, SICHUAN UNIVERSITY (CN) | 2022-10-13 | — | — | US | claimed |
| CN-115068624-A | Peptide dendrimer drug-carrying system and preparation method and application thereof | 重庆理工大学 | 2022-09-20 | — | — | CN | claimed |
| CN-105431135-A | Polymeric drug delivery system for treating surgical complications | TYRX INC | 2016-03-23 | — | — | CN | claimed |
| CN-102458640-A | Multi-phase microparticles and method for producing multi-phase microparticles | UNIV NANYANG TECH | 2012-05-16 | — | — | CN | claimed |
| EP-0145875-A2 | Gamma-aminobutyric acid transaminase inhibitors and processes for their preparation | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-06-26 | — | — | EP | claimed |
| US-12605459-B2 | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-4720058-A2 | BIFUNCTIONAL DEGRADERS AND USES THEREOF | Casma Therapeutics, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4711368-A1 | AZEPINE COMPOUND, AND COMPOSITION AND USE THEREOF | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2026-03-18 | — | — | EP | disclosed |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2026-03-05 | — | — | US | disclosed |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2025-12-25 | — | — | US | disclosed |
| US-20250367332-A1 | PSMA-TARGETED RADIOACTIVE METAL COMPLEX CONTAINING NITROAROMATIC HETEROCYCLIC GROUP AND PREPARATION METHOD | UNIV BEIJING NORMAL (CN) | 2025-12-04 | — | — | US | disclosed |
| US-5075099-A | Metal radionuclide chelating compounds for improved chelation kinetics | NEORX CORPORATION (US) | 1991-12-24 | — | — | US | disclosed |
| US-4988496-A | Metal radionuclide chelating compounds for improved chelation kinetics | NEORX CORPORATION (US) | 1991-01-29 | — | — | US | disclosed |
| EP-0344724-A2 | Metal radionuclide chelating compounds for improved chelation kinetics | NEORX CORPORATION (US) | 1989-12-06 | — | — | EP | disclosed |
| EP-0329481-A2 | Anchimeric radiometal chelating compounds | NEORX CORPORATION (US) | 1989-08-23 | — | — | EP | disclosed |
| US-4824974-A | Synthesis for the preparation of 4-amino-4,5-dihydro-2-furancarboxylic acid | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-04-25 | — | — | US | disclosed |
| US-4588825-A | Intermediates for the synthesis of 4-amino-4,5-dihydro-2-furancarboxylic acid | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-05-13 | — | — | US | disclosed |
| EP-0145875-A2 | Gamma-aminobutyric acid transaminase inhibitors and processes for their preparation | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324867-A1 | BENZODIAZEPINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | GABRA1, GABRA4, GABRR1 | PPARA 1366/4885PPARG 504/4885CTSK 4850/4885 |
| US-20250387504-A1 | ANTIBODY-DRUG CONJUGATES OF ANTINEOPLASTIC COMPOUNDS AND METHODS OF USE THEREOF | BID, BCL2, MCL1 | PPARA 3930/4885PPARG 3997/4885CTSK 3327/4885 |
| US-12605459-B2 | Protein-drug conjugates comprising camptothecin analogs and methods of use thereof | FOLH1, TGM2, SLC3A2 | PPARA 4456/4885PPARG 3064/4885CTSK 2554/4885 |
| US-20260061065-A1 | ANTIBODY DRUG CONJUGATES | FCGR2A, FCGR3B, BCL3 | PPARA 3847/4885PPARG 3994/4885CTSK 2216/4885 |
| US-20250367332-A1 | PSMA-TARGETED RADIOACTIVE METAL COMPLEX CONTAINING NITROAROMATIC HETEROCYCLIC GROUP AND PREPARATION METHOD | PSMA1, PSMA2, PSMA7 | PPARA 1925/4885PPARG 2134/4885CTSK 1234/4885 |
| US-12473291-B2 | Benzodiazepine compound, preparation method therefor, and use thereof in medicine | GABRA1, GABRA4, GABRR1 | PPARA 1366/4885PPARG 504/4885CTSK 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.